Compare

Innoviva, Inc. vs Ardelyx, Inc. vs Sinovac Biotech Ltd vs Arrowhead Pharmaceuticals, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearInnoviva, Inc.
INVA
Ardelyx, Inc.
ARDX
Sinovac Biotech Ltd
SVA
Arrowhead Pharmaceuticals, Inc.
ARWR
Year ended2025-12-312025-12-312025-12-312026-09-30
Revenue$411.33M$407.32M$386.01M$450.82M
Revenue growth (YoY)+14.7%+22.1%+6.8%-45.6%
Gross margin74.8%90.3% (computed)67.9%n/a
Operating margin39.8%-10.1%-127.0%-156.9%
Net margin65.9%-15.1%-51.5%-159.1%
Net income$271.17M-$61.60M-$198.84M-$717.13M
EPS (Diluted)$3.30-$0.26-$0.83-$5.11
Operating cash flow$196.93M-$42.48M-$512.18M-$271.95M
Free cash flow$195.80M-$43.98M-$561.10M-$283.94M
Cash & equivalents$550.94M$68.00M$488.25Mn/a
Total assets$1.64B$501.60M$8.54B$1.74B
Total liabilitiesn/a$334.65M$2.15Bn/a
Shareholders' equity$1.17B$166.95M$6.40B$50.50M
Return on year-end equity23.1%-36.9%-3.1%n/m
Shares outstanding74.64M244.35M71.86M141.29M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearInnoviva, Inc.Ardelyx, Inc.Sinovac Biotech LtdArrowhead Pharmaceuticals, Inc.
Latest$411.33M
Ended 2025-12-31
$407.32M
Ended 2025-12-31
$386.01M
Ended 2025-12-31
$450.82M
Ended 2026-09-30
1 year earlier$358.71M
Ended 2024-12-31
$333.62M
Ended 2024-12-31
$361.37M
Ended 2024-12-31
$829.45M
Ended 2025-09-30
2 years earlier$310.46M
Ended 2023-12-31
$124.46M
Ended 2023-12-31
$470.17M
Ended 2023-12-31
$3.55M
Ended 2024-09-30
3 years earlier$331.34M
Ended 2022-12-31
$52.16M
Ended 2022-12-31
$1.47B
Ended 2022-12-31
$240.74M
Ended 2023-09-30
4 years earlier$391.87M
Ended 2021-12-31
$10.10M
Ended 2021-12-31
$19.37B
Ended 2021-12-31
$243.23M
Ended 2022-09-30